

Selected Publications with Data from ACC PDX models

Mishra V, Singh A, Korzinkin M, Cheng X, Wing C, Sarkisova V, Koppayi AL, Pogorelshaya A, Glushchenko O, Sundaresan M, Thodima V, Carter J, Ito K, Scherle P, Trzcinska A, Ozerov I, Voles EE, Cole G, Pun FW, Shen L, Miao Y, Pearson AT, Lingen MW, Ruggeri B, Rosenberg AJ, Zhavoronkov A, Agrawal N, and Izumchenko E. PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. *J Exp Clin Cancer Res.* 2025 Jan 11;44(1):11.

Ciciro Y, Ragusa D, Nevado PT, Lattanzio R, Sala G, DesRochers T, Millard M, Andersson MK, Stenman G and Sala A. The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma. *FEBS Lett.* 2024 Jan;598(2):252-265.

Capone E, Perroti V, Cela I, Lattanzio R, Togni L, Rubini C, Caponio VCA, Muzio LL, Colasante M, Giansant F, Ippoliti R, Iacobelli S, Wick MJ, Burr NS, and Sala G. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma. *Oral Oncol.* 2024 Jan;148:106635.

Viragova S, Aparicio L, Palmerini P, Zhao J, Salazar LEV, Schurer A, Dhuri A, Sahoo D, Moskaluk CA, Rabadan R, and Dalerba P. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. *J Natl Cancer Inst.* 2023 Jul 6;115(7):838-852.

Sousa LG, McGrail D, Neto FL, Li K, Marques-Piubelli M, Ferri-Borgogno S, Dai H, Mitani Y, Burr NS, Cooper ZA, Kinneer K, Cortez MA, Lin S-Y, Bell D, El Naggar A, Burks J, and Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma reveals B7-H4 is a therapeutic target for aggressive tumors. *Clin Cancer Res.* 2023 Aug 15;29(16):3162-3171.

Guimaraes L, Webber L, Gaio E, Junior D, Goncalves, P, Wick M, Burr N, Squarize C, and Castilho R. Using PDX animal models to identify and stratify adenoid cystic carcinoma patients presenting an enhanced response to HDAC inhibitors. *Am J Cancer Res.* 2023 Jan 15; 13(1):143-160.

Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. *Cell Death Dis.* 2022 Aug 5;13(8):768.

Mandelbaum J, Shestopalov IA, Henderson RE, Chau NG, Knoechel B, Wick MJ, Zon LI. Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma. *J Exp Med.* 2018 Oct 1;215(10):2673-2685.

Andersson MK, Afshari MK, Andr n Y, Wick MJ, Stenman G. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling. *J Natl Cancer Inst.* 2017 Sep 1;109(9).

Chen C, Choudrey S, Wangsa D, Lescott CJ, Wilkins DJ, Sripadhan P, Liu X, Wangsa D, Ried T, Moskaluk C, Wick MJ, Glasgow E, Schlegel R, Agarwal S. A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug. *Sci Rep.* 2017 Sep 12;7(1):11410.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. *J Clin Oncol.* 2017 Jan 20;35(3):352-60.

Ling S, Rettig EM, Tan M, Chang X, Wang Z, Brait M, Bishop JA, Fertig EJ, Considine M, Wick MJ, Ha PK. Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. *Int J Oncol.* 2016 Jul 49(1):225-34.

Warner KA, Nör F, Acasigua GA, Martins MD, Zhang Z, McLean SA, Spector ME, Chepeha DB, Helman J, Wick MJ, Moskaluk CA, Castilho RM, Pearson AT, Wang S, Nör JE. Targeting MDM2 for treatment of adenoid cystic carcinoma. *Clin Cancer Res.* 2016 Jul 15;22(14):3550-9.

Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE. An oncogenic MYB feedback loop drives alternate fates in adenoid cystic carcinoma. *Nat Genet.* 2016 Feb 24;48(3):265-72

Stoek A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Farwell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. *Cancer Discov.* 2014 Oct 4(10):1154-67

Ivanov SV, Panaccione A, Brown B, Guo Y, Moskaluk CA, Wick MJ, Brown JL, Ivanova AV, Issaeva N, El-Naggar AK, Yarbrough WG. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. *Oncogene.* 2012 Oct 1.

Selected Posters

Xi S, Soulard P, Li Kai, Gu X, Kay Ibrahim, Hasson S, Yates C, Sadlish H, Lee J, Weng Z, Xu S, and Wager T. Effect of RGT-61159 on inhibition of oncogene c-MYB synthesis and tumor growth inhibition in a broad range of ACC PDX models, at well tolerated doses in rodents and non-human primates. *JCO* 42, 6107-6107(2024).

Humtsoe JO, Jones L, Naara S, Zammarchi F, Spardy Burr N, Van Berkel PH, Ha PK, Kang H. AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601). *Cancer Res* (2022) 82 (12_Supplement): LB084.

Carter J, Koichi I, Thodima V, Bhagwat N, Rager J, Spardy Burr N, Kaufman J, Ruggeri B, Scherle P, Vaddi, K. PRMT5 inhibition downregulates MYB and NOTCH1 signaling, key molecular drivers of adenoid cystic carcinoma. *Cancer Res* (2021) 81 (13_Supplement): 1138.

Ferrarotto R, Rauch R, Leibovich T, Shitrit A, Solomon O, Herz E, Walker R, Ho A, Kaye J. The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of NOTCH dysregulated tumors. *Annals of Oncology* (2021) 32 (suppl_5): S1211-S1226. [10.1016/annonc/annonc716](https://doi.org/10.1016/annonc/annonc716)

Ferrarotto R, Alpert G, Gluschnaider U, Rauch R, Mondshine A, Solomon O, Kramer B, Izumchenko E, Heymach J, Vergara-Silva A, Aster J, Davis M. AL101 mediated tumor inhibition in NOTCH mutated ACC PDX models. *Cancer Res*. 2019 Jul.

Dempsey Barber J, Samizadeh M, Jia N, Siders W, Kaplan J. Potential of mebendazole as an anti-tumor agent for adenoid cystic carcinoma and other rare cancers. *Cancer Res*. 2018 Jul.

Mangold A, Rundle M, Spardy Burr N, Moriarty A, Goncalves P, Castilho R, Ordentlich P, Kaufman J, Papadopoulos K, Wick M. Activity of entinostat alone and in combination with cisplatin in a panel of low passage adenoid cystic carcinoma patient-derived xenograft (PDX) models. AACR 2018 Proceedings.

Wick M, Meade J, Vaught T, Nehls M, Flores J, Kaufman J, Tolcher A, Rasco D, Patnaik A, Moskaluk C, Papadopoulos K. Utilization of low passage adenoid cystic PDX models to identify novel combination therapies. EORTC, 2014.

Meade J, Wick M, Vaught T, Carlile J, Tolcher A, Rasco D, Patnaik A, Kaufman J, Moskaluk C, Papadopoulos K. Utilization of low passage adenoid cystic carcinoma (ACC) models to identify novel therapies. EORTC, 2013.